An Explorative Study on Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable Non-small-cell Lung Carcinoma
Latest Information Update: 08 Mar 2023
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Mar 2023 Planned End Date changed from 1 Nov 2021 to 1 Nov 2023.
- 01 Mar 2023 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2023.
- 01 Mar 2023 Status changed from recruiting to active, no longer recruiting.